NasdaqCM - Nasdaq Real Time Price USD

Vivani Medical, Inc. (VANI)

Compare

1.1300

-0.0100

(-0.88%)

At close: February 12 at 4:00:01 PM EST

1.1526

+0.02

+(2.00%)

Pre-Market: 8:19:14 AM EST

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 29 days ago

IPWR

NZAUF

ELRRF
Vivani begins exenatide implant trial for obesity in Australia

The company plans to leverage research and development incentives from the Australian Government to offset the trial costs.

Medical Device Network last month

VANI
-0.88%
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

ALAMEDA, Calif., December 19, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Compa

Business Wire last month

VANI
-0.88%
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia

On Thursday, Vivani Medical Inc. (NASDAQ:VANI) initiated screening and enrollment at two centers in Australia for the first-in-human clinical trial, LIBERATE-1. The trial investigates the safety, tolerability, and full pharmacokinetic profile of an exenatide implant. Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Also Read: EXCLUSIVE: Vivani Medical Reveals P

Benzinga last month

VANI
-0.88%
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

ALAMEDA, Calif., December 04, 2024--Vivani Medical, Inc. (NASDAQ: VANI) (the "Company" or "Vivani"), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024.

Business Wire 2 months ago

VANI
-0.88%
Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 30% More Shares

Those following along with Vivani Medical, Inc. ( NASDAQ:VANI ) will no doubt be intrigued by the recent purchase of...

Simply Wall St. 2 months ago

VANI
-0.88%
Vivani Medical: Q3 Earnings Snapshot

ALAMEDA, Calif. AP) — Vivani Medical, Inc. VANI) on Wednesday reported a loss of $6 million in its third quarter.

Associated Press Finance 2 months ago

VANI
-0.88%
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

ALAMEDA, Calif., November 13, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.

Business Wire 2 months ago

VANI
-0.88%
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 3 months ago

VOXR

BVAXF

CIA
3 US Penny Stocks To Monitor In October 2024

As the major U.S. stock indexes hover near record levels, investors are keenly observing market movements and economic indicators for signs of stability and growth. Penny stocks, although an antiquated term, continue to capture interest by offering potential growth opportunities at lower price points. When these smaller or newer companies boast strong financial health and solid fundamentals, they present a unique chance to discover value in the market's less-traveled paths.

Simply Wall St. 3 months ago

VANI
-0.88%
RLMD

SNSE
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

ALAMEDA, Calif., October 22, 2024--Vivani Medical, Inc. (NASDAQ: VANI) (the "Company" or "Vivani"), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming events in October: (1) Partnership Opportunities in Drug Delivery (PODD), taking place in Boston on October 28 and 29, 2024 and (2) the ThinkEquity Conference, taking place in New York on October 30, 2024.

Business Wire 3 months ago

VANI
-0.88%
Vivani Medical obtains Australian approval to begin GLP-1 implant trial

The study will evaluate the safety, tolerability and pharmacokinetic characteristics of the company's exenatide implant.

Medical Device Network 4 months ago

VANI
-0.88%
Vivani Medical to Test Implant in Obese and Overweight Patients

By Daniella Parra Vivani Medical said it received regulatory approval in Australia for its GLP-1 (exenatide) implant, aimed at treating obese and overweight individuals. The trial will evaluate the safety, tolerability and pharmacokinetic profile of the implant, which is designed to offer comparable efficacy to semaglutide, the active ingredient in Ozempic and Wegovy, but with […]

Exec Edge 4 months ago

VANI
-0.88%
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

ALAMEDA, Calif., September 26, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee ("HREC") has approved and the Therapeutic Goods Administration ("TGA") in Australia has formally acknowledged a first in human clinical trial of the Company’s miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects.

Business Wire 4 months ago

VANI
-0.88%
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia

On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced that the Bellberry Human Research Ethics Committee has approved, and the Therapeutic Goods Administration in Australia has formally acknowledged a first-in-human clinical trial of the company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. What Happened: "Securing regulatory approval keeps us on schedule to initiate this trial in Australia in the fourth quarter of 2024," said Vivani President and CEO Ada

Benzinga 4 months ago

VANI
-0.88%
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

MIAMI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting c

GlobeNewswire 4 months ago

VGZ

AEMD

IMRN
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

ALAMEDA, Calif., September 23, 2024--Vivani Medical, Inc. (NASDAQ: VANI) (the "Company" or "Vivani"), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024.

Business Wire 4 months ago

VANI
-0.88%
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

ALAMEDA, Calif., September 04, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today reported positive preclinical liver fat results with its exenatide implant.

Business Wire 5 months ago

VANI
-0.88%
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity

On Wednesday, Vivani Medical, Inc. (NASDAQ:VANI) reported preclinical liver fat results with its exenatide implant for obese patients. Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand names Byetta and Bydureon BCise to treat type 2 diabetes. Also Read: EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use. “The reduction in liver fat observed preclinically with our miniature, subdermal exenatide implant provides further suppo

Benzinga 5 months ago

VANI
-0.88%
AZN
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ALAMEDA, Calif., August 28, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York.

Business Wire 5 months ago

VANI
-0.88%

Performance Overview

Return	VANI	S&P 500
YTD	-2.59%	+2.90%
1-Year	+7.62%	+20.51%
3-Year	-71.89%	+36.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vivani Medical, Inc. (VANI)

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

Vivani begins exenatide implant trial for obesity in Australia

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 30% More Shares

Vivani Medical: Q3 Earnings Snapshot

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

3 US Penny Stocks To Monitor In October 2024

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Vivani Medical obtains Australian approval to begin GLP-1 implant trial

Vivani Medical to Test Implant in Obese and Overweight Patients

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Performance Overview